Corrigendum to “925MO First-in-human phase I/Ib study of the oral Werner (WRN) helicase inhibitor HRO761 in patients (pts) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors: Interim safety and efficacy analysis from HRO761 single agent dose escalation” The organisers regret that in the original publication of this abstract the Table: 925MO was incorrectly formatted. The correctly formatted table is now given here. Annals of Oncology February 17, 2026 Original source
PET/CT-Guided Management of Immune Checkpoint Blockade and Post-Treatment Multi-Modal Profiling in Long-Term Responders with Metastatic Lung Cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM) We read with interest the report by Frost and colleagues evaluating a PET/CT-guided management strategy after at least 2 years of disease control on first-line immune checkpoint blockade (ICB) [1]. While addressing the critical need for de-escalation strategies, several methodological aspects warrant clarification. Annals of Oncology February 17, 2026 Original source
Refining risk assessment: bridging statistical innovation and clinical reality <p>Prostate Cancer and Prostatic Diseases, Published online: 15 February 2026; <a href="https://www.nature.com/articles/s41391-026-01088-6">doi:10.1038/s41391-026-01088-6</a></p>Refining risk assessment: bridging statistical innovation and clinical reality Prostate Cancer Journal February 16, 2026 Original source
Unlocking the promise of innate biology through the HLA-G/ILT2/ILT4 pathway <p>Inhibitory immune pathways have gained considerable attention following the clinical success of immune checkpoint inhibitors in cancer. While much focus has been placed on classical checkpoints such as programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4), alternative immunosuppressive mechanisms are increasingly recognized as contributors to immune evasion, tumor progression, and therapeutic resistance. Among… Journal for ImmunoTherapy of Cancer February 15, 2026 Original source
Artificial Intelligence in Oncology: From Tools to Teammates Artificial intelligence (AI) methods can be used as tools in oncology and cancer research. AI methods are being applied across all disciplines in cancer care, including pathology1, radiology2, and surgery3. Examples include image analysis tools which can be used for tumor diagnosis4. They can also be used for more complex applications, such as the prediction of molecular alterations directly from… Annals of Oncology February 13, 2026 Original source
Is there a future for Trop-2-targeted ADCs in urothelial carcinoma? The treatment landscape of advanced urothelial carcinoma (UC) has been transformed by the introduction of antibody–drug conjugates (ADCs). Enfortumab vedotin,1 a nectin-4-directed ADC with a monomethyl auristatin E (MMAE) payload, and disitamab vedotin,2 a human epidermal growth factor receptor 2-directed MMAE ADC, have both demonstrated high single-agent response rates in pretreated advanced disease. Combinations of these ADCs with immune checkpoint… Annals of Oncology February 13, 2026 Original source
To PET or not to PET, that is the question Lymphoma is one of the most chemosensitive tumors, but not all patients respond equally to the same chemotherapy. Therefore, individualized approaches are warranted,1 e.g. pre-treatment and post-treatment approaches. The former includes identification of prognostic factors2 and construction of prognostic indexes.1,3 The latter includes detection of measurable residual diseases and imaging response evaluation and further aims at treatment modification according to… Annals of Oncology February 13, 2026 Original source
Synthetic lethality of MCL-1 inhibition and CAR-T therapy in aggressive B-cell lymphoma <p>Leukemia, Published online: 12 February 2026; <a href="https://www.nature.com/articles/s41375-026-02884-8">doi:10.1038/s41375-026-02884-8</a></p>Synthetic lethality of MCL-1 inhibition and CAR-T therapy in aggressive B-cell lymphoma Leukemia Journal February 13, 2026 Original source
Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancer <p>Prostate Cancer and Prostatic Diseases, Published online: 12 February 2026; <a href="https://www.nature.com/articles/s41391-026-01076-w">doi:10.1038/s41391-026-01076-w</a></p>Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancer Prostate Cancer Journal February 12, 2026 Original source
Inherited resilience <p>Nature Reviews Cancer, Published online: 10 February 2026; <a href="https://www.nature.com/articles/s41568-026-00914-2">doi:10.1038/s41568-026-00914-2</a></p>Mutant haematopoietic stem cells display broad fitness variation, suggesting that protective mechanisms may limit clonal expansion and malignant transformation. Now, Agarwal et al. identify a germline noncoding variant that confers resilience to clonal haematopoiesis of indeterminate potential (CHIP) by dampening expression of the RNA-binding protein MSI2. Nature Reviews Cancer February 12, 2026 Original source
Efficacy and safety of pembrolizumab, lenvatinib, and reduced-dose gemcitabine/oxaliplatin as initial treatment for advanced biliary tract cancer: a multicenter, single-arm, prospective, phase II study Background <p>Biliary tract cancer (BTC) is an aggressive malignancy with limited treatment options and a poor prognosis. Although immune checkpoint inhibitors combined with chemotherapy have improved patient outcomes, their toxicity remains concerning. This phase II multicenter trial evaluated the efficacy and safety of pembrolizumab plus lenvatinib with a reduced-dose gemcitabine and oxaliplatin (GEMOX) regimen as a first-line therapy for advanced… Journal for ImmunoTherapy of Cancer February 11, 2026 Original source
Harnessing tumor acidity: innovative lactic acid-responsive promoter enables precision control of CAR-T cell activity in solid tumors Background <p>The acidic tumor microenvironment (TME) in solid tumors, driven by abnormal metabolism and lactic acid accumulation, suppresses chimeric antigen receptor-T (CAR-T) cell efficacy while posing safety risks from on-target, off-tumor toxicity (OTOT). This study aims to develop a novel CAR-T technology that leverages lactic acid as a tumor-specific trigger to achieve precise control of CAR activity. The objective is… Journal for ImmunoTherapy of Cancer February 11, 2026 Original source
Shared PRAME epitopes are T-cell targets in NUT carcinoma Background <p>NUT carcinoma is a rare but highly lethal solid tumor without an effective standard of care. NUT carcinoma is caused by bromodomain-containing <i>NUTM1</i> fusion oncogenes, most commonly <i>BRD4::NUTM1</i>. BRD4::NUTM1 recruits p300 to acetylate H3K27 forming expansive stretches of hyperacetylated chromatin called "megadomains" with the overexpression of corresponding oncogenes, including <i>MYC</i>. We hypothesized that transcriptional dysregulation caused by BRD4::NUTM1 would… Journal for ImmunoTherapy of Cancer February 11, 2026 Original source
Immunobiological mechanisms of action of oncolytic peptides <p>Oncolytic peptides (OLPs) constitute an emerging class of immunotherapeutics that combine direct cancer cell lysis with immune activation. Indeed, OLPs induce rapid immunogenic cell death by disrupting intracellular membranes, which culminates with the abundant release of malignant cell contents including immunostimulatory danger-associated molecular patterns. This results in the engagement of innate immune sensors that potently activate dendritic cells, leading to… Journal for ImmunoTherapy of Cancer February 11, 2026 Original source
CD4+ T cells facilitate the RT-induced abscopal effect by promoting antigen cross-presentation to CD8+ T cells at unirradiated tumor sites Background <p>The local effect of radiotherapy (RT) is enhanced by CD8<sup>+</sup> T-cell responses elicited through dendritic cell (DC)-mediated cross-presentation of tumor antigens, facilitated by RT-induced damage-associated molecular patterns. The abscopal effect—regression of non-irradiated tumors—has been observed clinically, particularly in combination with immune checkpoint blockade, although it remains uncommon. To better understand how to enhance this effect, we investigated two RT/α-programmed… Journal for ImmunoTherapy of Cancer February 11, 2026 Original source
Genetically engineered ErbB2 overexpression sensitizes organoid-derived tumors to checkpoint inhibition in a syngeneic model of gastric cancer Background <p>ERBB2/HER2 is overexpressed or mutated in ~15% of gastric cancers due to amplification or mutation of the <i>ERBB2</i> locus. While the tumor cell-intrinsic consequences of ERBB2 overexpression are well understood, much less is known about its effects on the tumor microenvironment.</p> Methods <p>We have developed genetically engineered ectopic and orthotopic syngeneic models of organoid-based gastric cancer that have allowed… Journal for ImmunoTherapy of Cancer February 11, 2026 Original source
DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix Background <p>Dual anti-CTLA-4/PD-1 inhibitors show efficacy in numerous malignancies. We are the first to report on the efficacy of ipilimumab-nivolumab immunotherapy in a dedicated cohort of patients with gynecologic clear cell carcinomas (CCCs), which are rare, aggressive cancers.</p> Methods <p>DART is a multicenter, multicohort phase II trial of ipilimumab (1 mg/kg intravenously every 6 weeks) plus nivolumab (240 mg intravenously… Journal for ImmunoTherapy of Cancer February 11, 2026 Original source
Phase 1 open-label study of ASP9801, an oncolytic virus, in patients with advanced or metastatic solid tumors Purpose <p>ASP9801, an oncolytic virus encoding interleukin-7 and interleukin-12, was assessed for safety, tolerability, pharmacokinetics, and antitumor activity in patients with advanced solid tumors in a Phase 1 study.</p> Methods <p>The study comprised Part 1 ASP9801 monotherapy dose escalation and Part 2 dose expansion with ASP9801 monotherapy or plus pembrolizumab. Each part was divided into Groups A (ASP9801 injection into… Journal for ImmunoTherapy of Cancer February 11, 2026 Original source